Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.

Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?

VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.

AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.